Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:11:53.359Z.
Calculation as of: 2026-10-06T15:11:53.359Z.
Quote observation: 2026-10-06T15:10:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b2d28e84da0c930e75004ae600b803967d1975629f72cad3bf33ad83c9831f21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Eikon Therapeutics, Inc. Common Stock
Market Cap
$418.76M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$410.68M
Price/FCF Ratio
N/A
TTM Avg
6.66
3Y Avg
6.66
5Y Avg
6.66
Market Cap
$407.27M
Price/FCF Ratio
N/A
TTM Avg
4285.33
3Y Avg
985.66
5Y Avg
501.76
Market Cap
$435.23M
Price/FCF Ratio
N/A
TTM Avg
53.84
3Y Avg
53.84
5Y Avg
53.84
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $418.76M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.68M | N/A | 6.66 | 6.66 | 6.66 |
| Neurogene Inc. (NGNE)vs › | $408.96M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | N/A | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $407.27M | N/A | 4285.33 | 985.66 | 501.76 |
| Carlsmed, Inc. (CARL)vs › | $403.15M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $435.23M | N/A | 53.84 | 53.84 | 53.84 |
| NeoGenomics, Inc. (NEO)vs › | $438.74M | N/A | 53.25 | 37.33 | 28.89 |
| NeuroPace, Inc. (NPCE)vs › | $441.17M | N/A | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $441.23M | N/A | 3.58 | 3.58 | 3.58 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
